Cardiology

Experts discuss how the 2025 ACC/AHA blood pressure guidelines may affect hypertension treatment decisions.

The FDA approved a once-monthly autoinjector for Lerochol (lerodalcibep-liga) and added language to the prescribing information noting that cardiovascular outcomes trials with statins and monoclonal...

A systematic review and meta-analysis presented at the 2026 American College of Cardiology Scientific Session evaluated whether tafamidis was associated with improved survival in patients aged 80 years and...

Primary care physicians can play a critical role in recognizing transthyretin amyloid cardiomyopathy, initiating an appropriate diagnostic evaluation, coordinating treatment, and helping patients and...

July 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a quick,...

A meta-analysis of randomized controlled trials presented at the American College of Cardiology’s Annual Scientific Session suggests RNA therapeutics reduce mortality and cardiac failure risk in...

In a landmark survival analysis of 596 consecutive patients with transthyretin amyloid cardiomyopathy, worsening NT-proBNP and heart failure hospitalization at 6 months were independently associated with...

A 1-year interim analysis of a phase 3, multicenter, open-label, 156-week extension study found overall reductions in systolic and diastolic blood pressure with atogepant 60 mg once daily in persons with...

In this expert interview, Deepak L. Bhatt, MD, MPH discusses guideline-based and emerging strategies for reducing recurrent ischemic stroke risk. From dietary interventions and blood pressure control to...

The FDA approved Baxfendy as an adjunctive treatment to lower blood pressure in adults with hypertension not adequately controlled on other antihypertensive medications.